Consistent with the results of previous clinical studies, our results reveal that ICIs combined with chemotherapy provide clinical benefits to patients with advanced HER-2 negative gastric adenocarcinoma (4–7). The gene discussed is ERBB2; the disease is gastric adenocarcinoma.